<div class="container">

<table style="width: 100%;"><tr>
<td>Certolizumabdat</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Data for the Certolizumab NMA-network discussed in Dias et al. (2013)</h2>

<h3>Description</h3>

<p>Data are available from a review of trials of certolizumab pegol (CZP)
for the treatment of rheumatoid arthritis in patients who had failed
on disease-modifying antirheumatic drugs, including methotrexate (MTX). 20
Twelve MTX controlled trials were identified, comparing 6 different
treatments with placebo. The primary outcome is improving by at least 50
of Rheumatology scale (ACR50) at 6 months. A trial-specificc covariate, the mean disease duration
in years for patients, is also given.
</p>


<h3>Usage</h3>

<pre><code class="language-R">Certolizumabdat
</code></pre>


<h3>Format</h3>

<p>An object of class <code>data.frame</code> with 12 rows and 9 columns.
</p>


<h3>Source</h3>

<p>Dias, S., Sutton, A.J., Welton, N.J. and Ades, A.E., 2013.
Evidence synthesis for decision making 3 heterogeneity-subgroups,
meta-regression, bias, and bias-adjustment. Medical Decision Making, 33(5),
pp.618-640.
</p>


</div>